TCGA-A1-A0SI-01A-11R-A144-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 21
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- INTERFERON_ALPHA_RESPONSE+0.510
- INTERFERON_GAMMA_RESPONSE+0.500
- MITOTIC_SPINDLE+0.370
- TNFA_SIGNALING_VIA_NFKB+0.370
- ALLOGRAFT_REJECTION+0.350
- APOPTOSIS+0.350
- INFLAMMATORY_RESPONSE+0.350
- COMPLEMENT+0.330
- IL6_JAK_STAT3_SIGNALING+0.330
Top 10 suppressed
- MYC_TARGETS_V1-0.370
- MYC_TARGETS_V2-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.280
- OXIDATIVE_PHOSPHORYLATION-0.270
- WNT_BETA_CATENIN_SIGNALING-0.220
- ESTROGEN_RESPONSE_EARLY-0.190
- PANCREAS_BETA_CELLS-0.190
- ESTROGEN_RESPONSE_LATE-0.120
- DNA_REPAIR-0.030
- MTORC1_SIGNALING-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A27M-01A-11R-A16F-07 | — | D | 0.860 |
| 2 | ERR2208954 | — | — | 0.854 |
| 3 | TCGA-AN-A0XW-01A-11R-A109-07 | — | C | 0.847 |
| 4 | MDT-AP-2029 | Med | Medulloblastoma | 0.840 |
| 5 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.839 |
| 6 | MDT-AP-0388 | Med | Medulloblastoma | 0.836 |
| 7 | SRR10899973 | — | — | 0.825 |
| 8 | SRR35579823 | — | D | 0.819 |
| 9 | s0112287 | — | — | 0.816 |
| 10 | MDT-AP-0390 | Med | Medulloblastoma | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| APOPTOSIS | 0.350 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |